{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:16:51Z","timestamp":1795047411844,"version":"4.10.2"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-32340-z","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T05:47:16Z","timestamp":1765777636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SLC45A2 drives prostate cancer progression through tumor promotion and immune suppression"],"prefix":"10.1038","volume":"16","author":[{"given":"Run","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"32340_CR1","doi-asserted-by":"publisher","first-page":"2364433","DOI":"10.1080\/15384047.2024.2364433","volume":"25","author":"NM Naranjo","year":"2024","unstructured":"Naranjo, N. M. et al. Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma. Cancer Biol. Ther. 25, 2364433. https:\/\/doi.org\/10.1080\/15384047.2024.2364433 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"32340_CR2","doi-asserted-by":"publisher","first-page":"e2322203121","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi, S. et al. Single-cell analysis of treatment-resistant prostate cancer: implications of cell state changes for cell surface antigen-targeted therapies. Proc. Natl. Acad. Sci. U S A. 121, e2322203121. https:\/\/doi.org\/10.1073\/pnas.2322203121 (2024).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"32340_CR3","doi-asserted-by":"publisher","first-page":"216824","DOI":"10.1016\/j.canlet.2024.216824","volume":"589","author":"T Yu","year":"2024","unstructured":"Yu, T. et al. Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming. Cancer Lett. 589, 216824. https:\/\/doi.org\/10.1016\/j.canlet.2024.216824 (2024).","journal-title":"Cancer Lett."},{"key":"32340_CR4","doi-asserted-by":"publisher","first-page":"e30941","DOI":"10.1016\/j.heliyon.2024.e30941","volume":"10","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Epigenetic-related gene-based prognostic model construction and validation in prostate adenocarcinoma. Heliyon 10, e30941. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30941 (2024).","journal-title":"Heliyon"},{"key":"32340_CR5","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/cbin.12191","volume":"48","author":"S Liu","year":"2024","unstructured":"Liu, S., Yu, Y., Xu, J., Wang, Y. & Li, D. Single-cell and bulk RNA-sequencing reveals mitosis-involved gene HAUS1 is a promising indicator for predicting prognosis and immune responses in prostate adenocarcinoma (PRAD). Cell. Biol. Int. 48, 1169\u20131184. https:\/\/doi.org\/10.1002\/cbin.12191 (2024).","journal-title":"Cell. Biol. Int."},{"key":"32340_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.apsb.2023.09.004","volume":"14","author":"J Le","year":"2024","unstructured":"Le, J., Chen, Y., Yang, W., Chen, L. & Ye, J. Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus. Acta Pharm. Sin B. 14, 437\u2013454. https:\/\/doi.org\/10.1016\/j.apsb.2023.09.004 (2024).","journal-title":"Acta Pharm. Sin B"},{"key":"32340_CR7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.tibs.2023.05.011","volume":"48","author":"A Schlessinger","year":"2023","unstructured":"Schlessinger, A., Zatorski, N., Hutchinson, K. & Colas, C. Targeting SLC transporters: small molecules as modulators and therapeutic opportunities. Trends Biochem. Sci. 48, 801\u2013814 (2023).","journal-title":"Trends Biochem. Sci."},{"key":"32340_CR8","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli, M. D., Bensimon, A. & Superti-Furga, G. A guide to plasma membrane solute carrier proteins. FEBS J. 288, 2784\u20132835 (2021).","journal-title":"FEBS J."},{"key":"32340_CR9","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","volume":"288","author":"MD Pizzagalli","year":"2021","unstructured":"Pizzagalli, M. D., Bensimon, A. & Superti-Furga, G. A guide to plasma membrane solute carrier proteins. FEBS J. 288, 2784\u20132835. https:\/\/doi.org\/10.1111\/febs.15531 (2021).","journal-title":"FEBS J."},{"key":"32340_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/pr.118.015735","volume":"72","author":"T Schumann","year":"2020","unstructured":"Schumann, T. et al. Solute carrier transporters as potential targets for the treatment of metabolic disease. Pharmacol. Rev. 72, 343\u2013379. https:\/\/doi.org\/10.1124\/pr.118.015735 (2020).","journal-title":"Pharmacol. Rev."},{"key":"32340_CR11","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.4049\/jimmunol.1400404","volume":"192","author":"JM Weiss","year":"2014","unstructured":"Weiss, J. M. et al. Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2\/\u03b1CD40 therapy. J. Immunol. 192, 5821\u20135829. https:\/\/doi.org\/10.4049\/jimmunol.1400404 (2014).","journal-title":"J. Immunol."},{"key":"32340_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12964-024-01826-0","volume":"22","author":"B Yang","year":"2024","unstructured":"Yang, B. et al. TRIM35 triggers cardiac remodeling by regulating SLC7A5-mediated amino acid transport and mTORC1 activation in fibroblasts. Cell. Commun. Signal. 22, 444. https:\/\/doi.org\/10.1186\/s12964-024-01826-0 (2024).","journal-title":"Cell. Commun. Signal."},{"key":"32340_CR13","doi-asserted-by":"publisher","unstructured":"Dvorak, V. et al. Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors. Cell. Chem. Biol. 30 https:\/\/doi.org\/10.1016\/j.chembiol.2023.06.029 (2023).","DOI":"10.1016\/j.chembiol.2023.06.029"},{"key":"32340_CR14","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-024-03358-9","volume":"19","author":"FC Klouwer","year":"2024","unstructured":"Klouwer, F. C. et al. Redefining the phenotype of alpha-methylacyl-CoA racemase (AMACR) deficiency. Orphanet J. Rare Dis. 19, 350 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"32340_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12032-024-02452-z","volume":"41","author":"L Yang","year":"2024","unstructured":"Yang, L., Shao, Y., Gao, T., Bajinka, O. & Yuan, X. Current advances in cancer energy metabolism under dietary restriction: a mini review. Med. Oncol. 41, 209 (2024).","journal-title":"Med. Oncol."},{"key":"32340_CR16","doi-asserted-by":"publisher","first-page":"e20180329","DOI":"10.1590\/1678-4685-gmb-2018-0329","volume":"43","author":"M N\u00f3brega","year":"2020","unstructured":"N\u00f3brega, M. et al. Association of polymorphisms of PTEN, AKT1, PI3K, AR, and AMACR genes in patients with prostate cancer. Genet. Mol. Biology. 43, e20180329 (2020).","journal-title":"Genet. Mol. Biology"},{"key":"32340_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12967-022-03632-z","volume":"20","author":"C Yan","year":"2022","unstructured":"Yan, C., Niu, Y., Li, F., Zhao, W. & Ma, L. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. J. Transl Med. 20, 455. https:\/\/doi.org\/10.1186\/s12967-022-03632-z (2022).","journal-title":"J. Transl Med."},{"key":"32340_CR18","doi-asserted-by":"publisher","first-page":"1341366","DOI":"10.3389\/fendo.2024.1341366","volume":"15","author":"Z Ma","year":"2024","unstructured":"Ma, Z. et al. Identification and analysis of mitochondria-related central genes in steroid-induced osteonecrosis of the femoral head, along with drug prediction. Front. Endocrinol. (Lausanne). 15, 1341366. https:\/\/doi.org\/10.3389\/fendo.2024.1341366 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"32340_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/1541-7786.MCR-22-0623","volume":"21","author":"E Khlebus","year":"2023","unstructured":"Khlebus, E. et al. Comparative tumor microenvironment analysis of primary and recurrent ovarian granulosa cell tumors. Mol. Cancer Res. 21, 483\u2013494. https:\/\/doi.org\/10.1158\/1541-7786.MCR-22-0623 (2023).","journal-title":"Mol. Cancer Res."},{"key":"32340_CR20","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1200\/JCO.2005.07.168","volume":"23","author":"DL Dai","year":"2005","unstructured":"Dai, D. L., Martinka, M. & Li, G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. 23, 1473\u20131482. https:\/\/doi.org\/10.1200\/JCO.2005.07.168 (2005).","journal-title":"J. Clin. Oncol."},{"key":"32340_CR21","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr","year":"2003","unstructured":"Dennis, G. Jr. et al. Database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3 (2003).","journal-title":"Genome Biol."},{"key":"32340_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"32340_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"32340_CR24","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013d592. https:\/\/doi.org\/10.1093\/nar\/gkac963 (2023).","journal-title":"Nucleic Acids Res."},{"key":"32340_CR25","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677 (2025).","journal-title":"Nucleic Acids Res."},{"key":"32340_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cell.2015.07.022","volume":"162","author":"A C\u00e9sar-Razquin","year":"2015","unstructured":"C\u00e9sar-Razquin, A. et al. A call for systematic research on solute carriers. Cell 162, 478\u2013487. https:\/\/doi.org\/10.1016\/j.cell.2015.07.022 (2015).","journal-title":"Cell"},{"key":"32340_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc.2017.84","volume":"17","author":"J Rotow","year":"2017","unstructured":"Rotow, J. & Bivona, T. G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer. 17, 637\u2013658. https:\/\/doi.org\/10.1038\/nrc.2017.84 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"32340_CR28","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","volume":"138","author":"L Schaller","year":"2019","unstructured":"Schaller, L. & Lauschke, V. M. The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum. Genet. 138, 1359\u20131377. https:\/\/doi.org\/10.1007\/s00439-019-02081-x (2019).","journal-title":"Hum. Genet."},{"key":"32340_CR29","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s00432-011-1050-9","volume":"137","author":"L Xie","year":"2011","unstructured":"Xie, L. et al. Solute carrier protein family May involve in radiation-induced radioresistance of non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 137, 1739\u20131747. https:\/\/doi.org\/10.1007\/s00432-011-1050-9 (2011).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"32340_CR30","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00280-013-2246-2","volume":"72","author":"B Mohelnikova-Duchonova","year":"2013","unstructured":"Mohelnikova-Duchonova, B. et al. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Cancer Chemother. Pharmacol. 72, 669\u2013682. https:\/\/doi.org\/10.1007\/s00280-013-2246-2 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"32340_CR31","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1042\/BJ20150751","volume":"473","author":"YD Bhutia","year":"2016","unstructured":"Bhutia, Y. D. et al. SLC transporters as a novel class of tumour suppressors: Identity, function and molecular mechanisms. Biochem. J. 473, 1113\u20131124. https:\/\/doi.org\/10.1042\/BJ20150751 (2016).","journal-title":"Biochem. J."},{"key":"32340_CR32","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10555-020-09879-6","volume":"39","author":"R Sutherland","year":"2020","unstructured":"Sutherland, R., Meeson, A. & Lowes, S. Solute transporters and malignancy: Establishing the role of uptake transporters in breast cancer and breast cancer metastasis. Cancer Metastasis Rev. 39, 919\u2013932. https:\/\/doi.org\/10.1007\/s10555-020-09879-6 (2020).","journal-title":"Cancer Metastasis Rev."},{"key":"32340_CR33","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.athoracsur.2015.02.013","volume":"99","author":"K Ikeda","year":"2015","unstructured":"Ikeda, K. et al. Prognostic significance of aberrant methylation of solute carrier gene family 5A8 in lung adenocarcinoma. Ann. Thorac. Surg. 99, 1755\u20131759. https:\/\/doi.org\/10.1016\/j.athoracsur.2015.02.013 (2015).","journal-title":"Ann. Thorac. Surg."},{"key":"32340_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21873\/cgp.20097","volume":"15","author":"S Lehrer","year":"2018","unstructured":"Lehrer, S. & Rheinstein, P. H. Expression of the vesicular monoamine transporter gene solute carrier family 18 member 1 (SLC18A1) in lung cancer. Cancer Genomics Proteom. 15, 387\u2013393. https:\/\/doi.org\/10.21873\/cgp.20097 (2018).","journal-title":"Cancer Genomics Proteom."},{"key":"32340_CR35","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1089\/dna.2019.5291","volume":"39","author":"W Guo","year":"2020","unstructured":"Guo, W. et al. Elevated SLC2A1 expression correlates with poor prognosis in patients with surgically resected lung adenocarcinoma: A study based on immunohistochemical analysis and bioinformatics. DNA Cell. Biol. 39, 631\u2013644. https:\/\/doi.org\/10.1089\/dna.2019.5291 (2020).","journal-title":"DNA Cell. Biol."},{"key":"32340_CR36","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Ablation of Proton\/Glucose exporter SLC45A2 enhances melanosomal Glycolysis to inhibit melanin biosynthesis and promote melanoma metastasis. J. Invest. Dermatol. 142 https:\/\/doi.org\/10.1016\/j.jid.2022.04.008 (2022).","DOI":"10.1016\/j.jid.2022.04.008"},{"key":"32340_CR37","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer. 20, 74\u201388. https:\/\/doi.org\/10.1038\/s41568-019-0216-7 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"32340_CR38","doi-asserted-by":"publisher","first-page":"107506","DOI":"10.1016\/j.celrep.2020.03.070","volume":"31","author":"N Journiac","year":"2020","unstructured":"Journiac, N. et al. Cell metabolic alterations due to Mcph1 mutation in microcephaly. Cell. Rep. 31, 107506. https:\/\/doi.org\/10.1016\/j.celrep.2020.03.070 (2020).","journal-title":"Cell. Rep."},{"key":"32340_CR39","doi-asserted-by":"publisher","first-page":"607444","DOI":"10.3389\/fcell.2020.607444","volume":"8","author":"P Fojt\u00edk","year":"2020","unstructured":"Fojt\u00edk, P., Beckerov\u00e1, D., Holomkov\u00e1, K., \u0160enfluk, M. & Rotrekl, V. Both hypoxia-inducible factor 1 and MAPK signaling pathway attenuate PI3K\/AKT via suppression of reactive oxygen species in human pluripotent stem cells. Front. Cell. Dev. Biol. 8, 607444. https:\/\/doi.org\/10.3389\/fcell.2020.607444 (2020).","journal-title":"Front. Cell. Dev. Biol."},{"key":"32340_CR40","doi-asserted-by":"publisher","DOI":"10.2174\/0113862073278304240614064748","author":"C Li","year":"2024","unstructured":"Li, C. et al. SLC16A3 is a prognostic marker and affects immune regulation in bladder cancer. Comb. Chem. High. Throughput Screen. https:\/\/doi.org\/10.2174\/0113862073278304240614064748 (2024).","journal-title":"Comb. Chem. High. Throughput Screen."},{"key":"32340_CR41","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1016\/j.labinv.2022.100022","volume":"103","author":"C Yan","year":"2023","unstructured":"Yan, C. et al. Upregulation of SLC12A3 and SLC12A9 mediated by the HCP5\/miR-140-5p axis confers aggressiveness and unfavorable prognosis in uveal melanoma. Lab. Invest. 103, 100022. https:\/\/doi.org\/10.1016\/j.labinv.2022.100022 (2023).","journal-title":"Lab. Invest."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32340-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32340-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:12:21Z","timestamp":1769213541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32340-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32340"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32340-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The protocol of experiments involving human participants has been approved by the medical ethical committee of The People\u2019s Hospital of Suzhou New District and has followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. Our study was reported as described by the ARRIVE guidelines. Informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"2538"}}